Compare APGE & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APGE | SHC |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | 2023 | 2020 |
| Metric | APGE | SHC |
|---|---|---|
| Price | $134.14 | $17.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $109.67 | $20.33 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $1,163,617,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | N/A | $6.00 |
| P/E Ratio | ★ N/A | $197.83 |
| Revenue Growth | N/A | ★ 5.74 |
| 52 Week Low | $34.34 | $11.00 |
| 52 Week High | $134.46 | $19.85 |
| Indicator | APGE | SHC |
|---|---|---|
| Relative Strength Index (RSI) | 79.86 | 55.17 |
| Support Level | $80.52 | $16.57 |
| Resistance Level | N/A | $17.80 |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | -1.62 | -0.07 |
| Stochastic Oscillator | 70.00 | 55.03 |
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.